Targovax reports Phase I/II data for ONCOS-102 in mesothelioma

Targovax A/S (OSE:TRVX) reported data from six patients with unresectable malignant pleural mesothelioma in the Phase I safety lead-in cohort of an open-label, Spanish Phase I/II trial showing that ONCOS-102 plus Alimta pemetrexed/cisplatin led to one partial response and two cases of stable disease. No safety concerns were reported and the company is now enrolling an additional 24 patients in the randomized Phase II portion of the trial to receive ONCOS-102 plus Alimta/cisplatin or Alimta/cisplatin alone...